JP7217631B2 - 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 - Google Patents

関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 Download PDF

Info

Publication number
JP7217631B2
JP7217631B2 JP2018562123A JP2018562123A JP7217631B2 JP 7217631 B2 JP7217631 B2 JP 7217631B2 JP 2018562123 A JP2018562123 A JP 2018562123A JP 2018562123 A JP2018562123 A JP 2018562123A JP 7217631 B2 JP7217631 B2 JP 7217631B2
Authority
JP
Japan
Prior art keywords
pad4
patient
antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523759A (ja
JP2019523759A5 (cg-RX-API-DMAC7.html
Inventor
レイチェル パトリシア モアテ
アレックス ゴッドウッド
イーサン ポール グラント
マーティン マイケル カリ シュウィッカート
カーロス チャベス
メイナ リャン
トーマス ミカエル マスティリン
ジョンビン ヤオ
カウスタブ ラネード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2019523759A publication Critical patent/JP2019523759A/ja
Publication of JP2019523759A5 publication Critical patent/JP2019523759A5/ja
Priority to JP2023008716A priority Critical patent/JP2023058524A/ja
Application granted granted Critical
Publication of JP7217631B2 publication Critical patent/JP7217631B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018562123A 2016-05-24 2017-05-23 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 Active JP7217631B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023008716A JP2023058524A (ja) 2016-05-24 2023-01-24 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340560P 2016-05-24 2016-05-24
US62/340,560 2016-05-24
PCT/EP2017/062479 WO2017202879A1 (en) 2016-05-24 2017-05-23 Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023008716A Division JP2023058524A (ja) 2016-05-24 2023-01-24 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体

Publications (3)

Publication Number Publication Date
JP2019523759A JP2019523759A (ja) 2019-08-29
JP2019523759A5 JP2019523759A5 (cg-RX-API-DMAC7.html) 2020-07-02
JP7217631B2 true JP7217631B2 (ja) 2023-02-03

Family

ID=59009670

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562123A Active JP7217631B2 (ja) 2016-05-24 2017-05-23 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体
JP2023008716A Ceased JP2023058524A (ja) 2016-05-24 2023-01-24 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023008716A Ceased JP2023058524A (ja) 2016-05-24 2023-01-24 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体

Country Status (7)

Country Link
US (2) US11613580B2 (cg-RX-API-DMAC7.html)
EP (1) EP3464358A1 (cg-RX-API-DMAC7.html)
JP (2) JP7217631B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017270027B2 (cg-RX-API-DMAC7.html)
CA (1) CA3024910A1 (cg-RX-API-DMAC7.html)
MA (1) MA45112A (cg-RX-API-DMAC7.html)
WO (1) WO2017202879A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023058524A (ja) * 2016-05-24 2023-04-25 メディミューン リミテッド 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3924736A1 (en) * 2019-02-15 2021-12-22 Inova Diagnostics, Inc. Compositions and methods for diagnosing and assessing rheumatoid arthritis
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
CN111458522B (zh) * 2020-04-20 2024-01-09 杭州英邈生物科技有限公司 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用
CN111733151B (zh) * 2020-07-13 2021-11-12 山东新创生物科技有限公司 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009156615A (ja) 2007-12-25 2009-07-16 Tokyo Metropolitan Foundation For Social Welfare & Public Health Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法
US20130101611A1 (en) 2009-11-25 2013-04-25 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
US20140127720A1 (en) 2012-11-05 2014-05-08 The Johns Hopkins University Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
WO2015177097A1 (en) 2014-05-19 2015-11-26 Medimmune Limited Treatment for rheumatoid arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
WO2004110244A2 (en) 2003-05-08 2004-12-23 Vanderbilt University A gene equation to diagnose rheumatoid arthritis
EP1999152B1 (en) 2006-03-27 2012-09-19 Medimmune Limited Binding member for gm-csf receptor
ES2483724T3 (es) * 2009-03-30 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarcadores, métodos y kits para el diagnóstico de artritis reumatoide
ES2660776T3 (es) 2011-10-10 2018-03-26 Medimmune Limited Tratamiento para la artritis reumatoide
US11613580B2 (en) * 2016-05-24 2023-03-28 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009156615A (ja) 2007-12-25 2009-07-16 Tokyo Metropolitan Foundation For Social Welfare & Public Health Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法
US20130101611A1 (en) 2009-11-25 2013-04-25 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
US20140127720A1 (en) 2012-11-05 2014-05-08 The Johns Hopkins University Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
WO2015177097A1 (en) 2014-05-19 2015-11-26 Medimmune Limited Treatment for rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ann. Rheum. Dis. (2013) vol.72, issue 9, p.1445-1452

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023058524A (ja) * 2016-05-24 2023-04-25 メディミューン リミテッド 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体

Also Published As

Publication number Publication date
CA3024910A1 (en) 2017-11-30
AU2017270027A1 (en) 2018-12-06
AU2017270027B2 (en) 2024-07-11
US20200317793A1 (en) 2020-10-08
US11613580B2 (en) 2023-03-28
EP3464358A1 (en) 2019-04-10
WO2017202879A1 (en) 2017-11-30
JP2019523759A (ja) 2019-08-29
US20230303707A1 (en) 2023-09-28
MA45112A (fr) 2019-04-10
JP2023058524A (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
JP7153775B2 (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
US20230303707A1 (en) Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
Cavazzana et al. Systemic sclerosis-specific antibodies: novel and classical biomarkers
US20220144935A1 (en) Ccl20 as a predictor of clinical response to il23-antagonists
JP2011524977A (ja) ループスのためのバイオマーカー
US20230204577A1 (en) Anti-pad2 antibody for treating and evaluating autoimmune and inflammatory diseases
EP2336769A1 (en) Trigger assay for differentiating between rheumatic and non-rheumatic disorders
JP2018538249A (ja) 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
JP2016508607A (ja) リウマチ性関節炎の診断方法
Di Caprio et al. The potential role of serum polyclonal free light chains as markers of immune activation in psoriatic patients
US20220373539A1 (en) Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
Ibrahim et al. Evaluating the Cartilage Oligomeric Matrix Protein Levels in Sera of Iraqi Patients with Rheumatoid Arthritis
Suzuki et al. AB0247 Evaluation of rheumatoid arthritis cases with high anti-ccp antibody level
Taneja et al. Fatigue in Rheumatoid Arthritis as Measured by BRAF-MDQ Score and its Relation to Serum Interleukin-6 Level
WO2019018394A1 (en) TREATMENT OF RHEUMATOID ARTHRITIS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230124

R150 Certificate of patent or registration of utility model

Ref document number: 7217631

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150